TRILEPTAL provides a strong foundation for partial seizure control in adult patients newly diagnosed with epilepsy Reduction in frequency of partial seizures1,2

Adult Efficacy Pediatric Efficacy First-line Use TRILEPTAL vs CBZ

	A low discontinuation rate (3.5%) due to adverse events (AEs) was observed
	No patients discontinued treatment due to behavioral, psychiatric, or cognitive AEs

NEXT: See results of a 3-year, open-label study

References:

1.		Data on file. Novartis Pharmaceuticals Corporation, East Hanover, NJ.
2.		Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 1997;27:195-204.